{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:46:23Z","timestamp":1786488383200,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Asparaginase is a critical component of therapy for acute lymphoblastic leukemia\/lymphoma but is associated with hypersensitivity reactions. Severe reactions necessitate a transition to an <jats:italic toggle=\"yes\">Erwinia<\/jats:italic> asparaginase product, which requires more frequent dosing and higher costs. Children\u2019s Hospital Colorado implemented universal pegaspargase premedication in May 2020 and a retrospective analysis was conducted to compare the rates of transition to <jats:italic toggle=\"yes\">Erwinia<\/jats:italic> products and hypersensitivity reactions between the preimplementation and postimplementation cohorts. In this large single-institution experience, universal premedication did not impact rates of <jats:italic toggle=\"yes\">Erwinia<\/jats:italic> transition or hypersensitivity reactions.<\/jats:p>","DOI":"10.1097\/mph.0000000000003034","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:00:08Z","timestamp":1744722008000},"page":"e181-e186","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Universal Premedication Does Not Impact Transition to Short-acting Asparaginase or Incidence of Hypersensitivity to Pegylated Asparaginase: A Single-institution Experience"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3599-3447","authenticated-orcid":false,"given":"Lindsey A.","family":"Murphy","sequence":"first","affiliation":[{"name":"Department of Pediatrics, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanette K.","family":"Bradley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allie N.","family":"Elozory","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Hospital Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexiang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado Cancer Center, Biostatistics Shared Resource"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-7490","authenticated-orcid":false,"given":"Kelly E.","family":"Faulk","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Center for Cancer and Blood Disorders, Children\u2019s Hospital Colorado, University of Colorado, Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"R1-20250623","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"R2-20250623","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22225","article-title":"Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia","volume":"54","author":"Vrooman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R3-20250623","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40272-015-0129-1","article-title":"Allergic reactions associated with intravenous versus intramuscular pegaspargase: a retrospective chart review","volume":"17","author":"Abbott","year":"2015","journal-title":"Paediatr Drugs"},{"key":"R4-20250623","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children\u2019s Cancer Group Study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"R5-20250623","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2013-01-480822","article-title":"Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children\u2019s Oncology Group","volume":"122","author":"Salzer","year":"2013","journal-title":"Blood"},{"key":"R6-20250623","doi-asserted-by":"crossref","first-page":"e27797","DOI":"10.1002\/pbc.27797","article-title":"Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions","volume":"66","author":"Cooper","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20250623","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1080\/10428194.2019.1608530","article-title":"A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage","volume":"60","author":"Marini","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R8-20250623","first-page":"232","article-title":"Efficacy of a standardized premedication and therapeutic drug monitoring protocol for pegaspargase to prevent hypersensitivity reactions","volume":"27","author":"Babcock","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"supp 1","key":"R9-20250623","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1182\/blood-2022-158844","article-title":"Universal premedication for pegylated (PEG)-asparaginase treatment in children with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LLy) has no impact on frequency of hypersensitivity reactions","volume":"140","author":"Fajardo","year":"2022","journal-title":"Blood"},{"key":"R10-20250623","doi-asserted-by":"crossref","first-page":"e30716","DOI":"10.1002\/pbc.30716","article-title":"Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia\/lymphoma therapy: a side-by-side comparison","volume":"71","author":"Menig","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20250623","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1080\/10428194.2017.1386305","article-title":"Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia","volume":"59","author":"Salzer","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"R12-20250623","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"R13-20250623","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-143248","article-title":"Premedication and longer infusion time do not reduce the incidence of hypersensitivity reactions to pegaspargase","volume":"136","author":"Hughes","year":"2020","journal-title":"Blood"},{"key":"R14-20250623","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.12688\/f1000research.19298.1","article-title":"Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication","volume":"8","author":"Losasso","year":"2019","journal-title":"F1000Res"},{"key":"R15-20250623","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1043454217741868","article-title":"Clinical characteristics of intravenous PEG-asparaginase hypersensitivity reactions in patients undergoing treatment for acute lymphoblastic leukemia [Formula: see text]","volume":"35","author":"Browne","year":"2018","journal-title":"J Pediatr Oncol Nurs"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:00:17Z","timestamp":1750690817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003034","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"2024-10-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}